The Fort Worth Press - Who should get paid for nature's sequenced genes?

USD -
AED 3.672497
AFN 65.496392
ALL 80.950045
AMD 366.423744
AOA 918.000162
ARS 1499.744031
AUD 1.420989
AWG 1.8
AZN 1.699932
BAM 1.697824
BBD 2.017891
BDT 124.016338
BHD 0.377796
BIF 2994.283829
BMD 1
BND 1.284641
BOB 12.117713
BRL 5.110079
BSD 1.001871
BTN 95.346152
BWP 13.550126
BYN 2.966287
BYR 19600
BZD 2.01494
CAD 1.401975
CDF 2260.000304
CHF 0.811025
CLF 0.023195
CLP 915.880237
CNY 6.74905
CNH 6.746405
COP 3160.36
CRC 455.750926
CUC 1
CUP 26.5
CVE 95.718223
CZK 21.04795
DJF 178.411296
DKK 6.48647
DOP 58.379523
DZD 133.069676
EGP 49.781403
ERN 15
ETB 161.7072
EUR 0.86772
FJD 2.21395
FKP 0.743241
GBP 0.743915
GEL 2.614958
GGP 0.743241
GHS 11.776297
GIP 0.743241
GMD 74.000045
GNF 8798.496547
GTQ 7.644462
GYD 209.601111
HKD 7.845145
HNL 26.852845
HRK 6.538201
HTG 130.990152
HUF 317.973979
IDR 17878.8
ILS 3.00728
IMP 0.743241
INR 95.24685
IQD 1312.470159
IRR 1374850.000229
ISK 123.560122
JEP 0.743241
JMD 158.809665
JOD 0.709002
JPY 158.381499
KES 129.413261
KGS 87.450129
KHR 4064.574925
KMF 426.999707
KRW 1417.704991
KWD 0.309006
KYD 0.834936
KZT 469.48422
LAK 22637.365499
LBP 89717.564641
LKR 336.535164
LRD 180.841182
LSL 16.341492
LTL 2.95274
LVL 0.60489
LYD 6.38659
MAD 9.347628
MDL 17.432256
MGA 4307.49732
MKD 53.409668
MMK 2099.552715
MNT 3596.040078
MOP 8.095403
MRU 40.165112
MUR 47.07029
MVR 15.459779
MWK 1737.235719
MXN 17.17252
MYR 4.0911
MZN 63.902631
NAD 16.341492
NGN 1364.690247
NIO 36.866479
NOK 9.524965
NPR 152.554158
NZD 1.702835
OMR 0.384495
PAB 1.001866
PEN 3.386533
PGK 4.426427
PHP 60.911017
PKR 278.144356
PLN 3.732765
PYG 5959.485913
QAR 3.6622
RON 4.560696
RSD 101.822965
RUB 82.152892
RWF 1471.771656
SAR 3.753349
SBD 8.068348
SCR 14.492263
SDG 600.502614
SEK 9.497301
SGD 1.281575
SLE 24.600298
SOS 572.596782
SRD 37.8665
STD 20697.981008
STN 21.268377
SVC 8.766044
SZL 16.328036
THB 33.057501
TJS 9.242241
TMT 3.505
TND 2.938406
TRY 47.704802
TTD 6.78331
TWD 32.289959
TZS 2647.503048
UAH 44.861256
UGX 3731.93281
UYU 40.348973
UZS 11939.75433
VES 754.21125
VND 26197.5
VUV 119.010387
WST 2.728415
XAF 569.434305
XAG 0.015545
XAU 0.000232
XCD 2.70255
XCG 1.805642
XDR 0.708194
XOF 569.434305
XPF 103.529248
YER 236.849903
ZAR 16.286398
ZMK 9001.200564
ZMW 19.060806
ZWL 321.999592
  • GSK

    0.7100

    52.17

    +1.36%

  • RIO

    -1.8600

    99.65

    -1.87%

  • BCC

    -0.5400

    84.26

    -0.64%

  • RBGPF

    0.0000

    69.74

    0%

  • CMSD

    -0.0600

    21.98

    -0.27%

  • AZN

    -0.4300

    161.07

    -0.27%

  • RELX

    -0.8600

    35.75

    -2.41%

  • BCE

    0.7100

    22.77

    +3.12%

  • NGG

    0.1500

    80.41

    +0.19%

  • JRI

    -0.0100

    12.66

    -0.08%

  • BP

    1.0200

    42.23

    +2.42%

  • RYCEF

    -0.3800

    20.62

    -1.84%

  • BTI

    -0.5400

    58.73

    -0.92%

  • VOD

    0.6900

    16

    +4.31%

  • CMSC

    -0.0100

    21.72

    -0.05%

Who should get paid for nature's sequenced genes?
Who should get paid for nature's sequenced genes? / Photo: © AFP/File

Who should get paid for nature's sequenced genes?

Much of the vanilla that flavors our ice cream today is artificial, derived from the genetic signature of a plant that hundreds of years ago was known only to an Indigenous Mexican tribe.

Text size:

The plant's sequenced genomic information, available on public databases, was used as the basis for a synthetic flavoring that today competes with vanilla grown in several countries, mainly by small-scale farmers.

Few, if any, benefits of the lucrative scientific advance have trickled down to the communities that gave us vanilla in the first place.

"Wild genetic resources and pharmaceuticals ... are a multi-multi-billion dollar businesses. They clearly are profitable... that's not in dispute," Charles Barber of the World Resources Institute think tank told AFP.

"A great deal of really valuable information has fed into the system from research and utilization of wild genetic resources. And there is no mechanism currently to compensate the people where this information is coming from" in the form of digitally sequenced data, he added.

Much of the information comes from poor countries.

Fair sharing of the gains derived from digitally-stored genetic sequencing data has been a headache for negotiators at the COP16 biodiversity summit into its second week in Cali, Colombia.

At the last conference, in Montreal in 2022, 196 country parties to the UN's Convention on Biological Diversity (CBD) agreed to create a benefit-sharing mechanism for the use of digital sequence information (DSI).

Two years later, they still need to resolve such basic questions as who pays, how much, into which fund, and to whom does the money go?

- 'Cheap and very fast' -

The issue is a complex one.

There is little debate that genetic data-sharing on mostly free-access platforms is crucial for human advancement through medicine and vaccine development, for example.

But how to quantify the value of the sequenced information itself? And should the first people to discover a plant's particular usefulness be compensated?

"Sequencing technology has become so advanced that you can go with a... handheld device a little bit bigger than a cell phone and you can literally sequence a genome in an hour or two and upload it as you sequence it," Pierre du Plessis, a DSI expert and former negotiator for African countries at the CBD told AFP.

These gene sequences are then uploaded to databases which artificial intelligence can mine for potential leads for product development.

DSI is worth an estimated hundreds of billions of dollars a year. And there is a lot of it out there.

"Once the sequence is put into a public database, generally, no benefit-sharing obligations apply," Nithin Ramakrishnan, a researcher with the Third World Network, an advocacy NGO for developing countries, told AFP in Cali.

"Like when the sandalwood sequence information is available in the database whether India wants to share its sandalwood... with a cosmetic company or not, doesn't matter.

- Mandatory -

A point of contention in Cali is a demand from developing countries that payment for DSI use be mandatory, perhaps through a one-percent levy on profits from drugs, cosmetics or other products.

They also want guarantees of non-monetary benefits such as access to vaccines produced from genetic information sequenced from viruses and other pathogens.

"We want real understanding, sector-specific understanding of what non-monetary benefits will be shared and we want the system to be obligatory -- the users should have some form of obligation to share benefits," said Ramakrishnan.

Another sticking point is access for Indigenous people and local communities to DSI funds.

Developing countries want the information on genetic databases to be traceable and "answerable to governments" of the countries where it comes from, said Ramakrishnan.

But rich nations and many researchers oppose such a model which they fear will be too onerous, potentially putting the brakes on scientific pursuits that could benefit all humankind.

With such divergent points of view, observers are doubtful the Cali COP will emerge with any firm decisions on the outstanding questions by closing time on Friday.

The World Wildlife Fund has said "many more rounds of negotiations appear necessary" on DSI.

Added Barber: "I think it's not going to all get solved here."

T.Harrison--TFWP